DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Clinical trials for DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED trials appear
Sign up with your email to follow new studies for DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New CAR-T therapy shows promise for Tough-to-Treat blood cancers
Disease control OngoingThis early-stage study is testing a new type of cell therapy called P-CD19CD20-ALLO1 for people with certain B-cell cancers (like diffuse large B-cell lymphoma) that have come back or not responded to standard treatments. The therapy uses donor immune cells that are specially des…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE1 • Sponsor: Poseida Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 08:20 UTC
-
Promising combo aims to stop aggressive lymphoma in its tracks
Disease control OngoingThis study tests whether adding the drug venetoclax to standard chemotherapy can help prevent high-grade B-cell lymphomas from returning or getting worse. About 363 adults with specific aggressive lymphoma types will receive either the usual chemo or the usual chemo plus venetocl…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 08:09 UTC
-
New combo therapy shows promise for tough lymphoma
Disease control OngoingThis early-phase study tests whether adding the drug acalabrutinib to a type of immune cell therapy (CAR T-cells) can safely treat B-cell lymphoma, a cancer of the immune system. About 23 adults with certain aggressive or slow-growing lymphomas will receive the combination. The g…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE1, PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 26, 2026 08:09 UTC
-
Could an oral drug boost chemo for seniors with lymphoma?
Disease control OngoingThis study looks at whether adding an oral medication (CC-486, or oral azacitidine) to a standard reduced-dose chemo regimen (R-miniCHOP) can help people aged 75 and older with newly diagnosed aggressive B-cell lymphomas. The goal is to see if the combination improves how long pa…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:53 UTC
-
New combo therapy aims to boost immune attack on tough lymphomas
Disease control OngoingThis phase 2 trial tests whether adding varlilumab to nivolumab helps people with aggressive B-cell lymphomas that have returned or not responded to standard therapy. About 54 participants will receive either nivolumab alone or nivolumab plus varlilumab. The goal is to see if the…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:40 UTC
-
Tiny chip could spot lymphoma return early
Knowledge-focused OngoingThis study tests a nanochip technology to see if it can better monitor how well treatment is working and detect if lymphoma comes back in people with diffuse large B-cell lymphoma. About 73 participants will provide blood samples during their standard chemotherapy. The goal is to…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: NA • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated May 26, 2026 08:07 UTC